Objective: To observe the clinical efficacy and effect of Jinlida granule combined with Tongxinluo capsule on traditional Chinese medicine (TCM) syndromes

glucose metabolism

lipid metabolism and levels of interleukin-6(IL-6) in serum of patients with non-proliferative retinopathy of type 2 diabetes. Method: The 62 patients with non-proliferative retinopathy of type 2 diabetes were randomly divided into two groups

and all of them were given with basic treatment. The control group (32 patients) were treated with calcium hydroxybenzene sulfonate capsule

and the treatment group (30 patients) were treated with Jinlida granule combined with Tongxinluo capsule on the basis of control group. After 12 weeks

clinical efficacy

TCM syndromes improvement

fasting plasma glucose (FPG)

2 h postprandial blood glucose (2 hPG)

glycosylated hemoglobin (HbA1c)

triacylglycerol (TG)

total cholesterol (TC)

high-density lipoprotein-C (HDL-C)

low-density lipoprotein-C (LDL-C)

insulin resistance index (HOMA-IR) and IL-6 in two groups were observed and compared. Result: The clinical efficacy and the improvement of TCM syndromes in treatment group were significantly better than those in control group (P<0.05). The FPG

2 hPG

HbA1c

TG

TC

HDL-C

insulin resistance index and IL-6 were significantly decreased

and the HDL-C was significantly increased in both groups after treatment

and the treatment group were better than control group (P<0.05). Conclusion: Jinlida granule combined with Tongxinluo capsule has a significant therapeutic effect on non-proliferative retinopathy of type 2 diabetes

and the mechanism may be related to regulating glucose and lipid metabolism

improving insulin resistance and reducing serum inflammatory factors.